A randomized clinical study found that one dose of psilocybin plus psychotherapy led to greater abstinence and more cocaine-free days than an active placebo among people seeking to quit
The landscape of stimulant addiction treatment remains sparse, and a new clinical trial has introduced a potentially transformative approach. In a randomized study published in JAMA Network Open, researchers tested whether a single administration of psilocybin—the psychoactive compound in “magic mushrooms”—could help people with cocaine use disorder reduce or stop using cocaine.
This research matters because there are currently no approved pharmacotherapies for stimulant dependence, and overdose deaths involving stimulants are increasing worldwide.
The trial enrolled forty adults who met specific criteria: age over 25, recent cocaine use on at least four days in the prior month, and a stated desire to quit.
Participants were randomly assigned to receive either a single high dose of psilocybin or an active comparator, diphenhydramine, together with a structured course of psychotherapy. The protocol included preparatory sessions, an all-day dosing session, and multiple integration visits. Follow-up assessments were conducted at 90 days and 180 days after the final therapy visit to measure sustained outcomes.
Trial results and measured benefits
Across the follow-up period, those who received psilocybin plus psychotherapy achieved significantly higher rates of abstinence and reported more cocaine-free days than the group given the active comparator. The study observed that recipients of psilocybin were more likely to remain abstinent and to delay relapse compared with participants who received diphenhydramine. Importantly, outcomes were corroborated by both self-report and objective drug testing during follow-up, and no serious treatment-related adverse events were reported in the trial sample.
How psilocybin may support behavior change
Researchers and neuroscientists propose that the therapeutic effect of psilocybin does not come from replacing or blocking the same receptors targeted by stimulants. Instead, psilocybin appears to induce an altered state of consciousness that can catalyze psychological shifts. Experts suggest the drug may increase neuroplasticity and psychological flexibility, enabling individuals to break rigid patterns of impulsive behavior associated with addiction. Unlike maintenance medication models that substitute a safer molecule, psilocybin is viewed as a potential single-session catalyst that, when paired with therapy, helps people revise perspectives and reduce substance use.
Psychotherapy and trial design considerations
The study paired medication with an intensive course of psychotherapy, including preparation and integration sessions designed to help participants process their experiences. Investigators also recruited people seeking to quit cocaine without advertising psychedelic treatment specifically, aiming to limit expectation bias. The trial population notably included a majority of low-income Black men, addressing long-standing concerns about the underrepresentation of diverse groups in psychedelic research. This recruitment approach may increase the generalizability of findings to communities most affected by cocaine-related criminal justice involvement.
Limitations and safety cautions
Despite encouraging outcomes, the trial has constraints that require careful interpretation. The protocol excluded individuals taking antidepressants and those with a history of bipolar disorder, uncontrolled high blood pressure, or active severe mood disorders, so the results do not establish efficacy for people with common comorbid depression or anxiety. Experts warn about the risk of expanding psychedelic access without safeguards, especially among vulnerable populations. Larger, more inclusive clinical trials are necessary to confirm benefit, define safety parameters, and determine how psilocybin compares with or complements other psychosocial interventions.
Public health implications and next steps
If replicated at scale, these findings could shift treatment strategies for stimulant dependence, offering a new tool where pharmacologic options are currently absent. The rise in global cocaine production and stimulant-involved overdose deaths heightens the urgency for innovations that reduce harm and improve recovery. Researchers emphasize that the present results are preliminary but promising, and they call for multi-site, larger trials to validate effectiveness and safety. In parallel, policymakers and clinicians should weigh how to integrate psychedelic-assisted therapy into care pathways while safeguarding participants and communities.
